Diamond Therapeutics Receives Multi-Million Dollar US Government Funding for Phase 2 Clinical Trial of Anxiety Treatment

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Diamond Therapeutics, a clinical-stage drug development company that advances innovative mental health therapeutics using psilocybin and other novel neuroplastogens, has received a multi-million dollar funding award from the Advanced Research Projects Agency for Health (ARPA-H) for the company’s phase 2 clinical trial of a treatment for generalized anxiety disorder (GAD).

Diamond Therapeutics presented at the OBIO® Investment Summit.

Read more
Arsheen Kaur
Next

Ontario Investing $5 Million to Strengthen Province’s Position as a Global Leader in Life Sciences